-+ 0.00%
-+ 0.00%
-+ 0.00%

60 Degrees Pharmaceuticals Says It Submitted Statement Of Interest To FDA For Commissioner's National Priority Voucher For ARAKODA In Babesiosis; DSMB Interim Analysis Of Phase 2 Trial Scheduled October 1, Targets sNDA Submission In March-April 2027

Benzinga·09/14/2026 20:11:57
Listen to the news